459 lines
28 KiB
HTML
459 lines
28 KiB
HTML
<!DOCTYPE html>
|
||
<html lang="zh-CN" data-theme="night">
|
||
<head>
|
||
<meta charset="UTF-8">
|
||
<meta name="viewport" content="width=device-width, initial-scale=1.0">
|
||
<title>深度行研：盐酸哌甲酯概念</title>
|
||
<script src="https://cdn.tailwindcss.com"></script>
|
||
<link href="https://cdn.jsdelivr.net/npm/daisyui@4.10.2/dist/full.min.css" rel="stylesheet" type="text/css" />
|
||
<script defer src="https://cdn.jsdelivr.net/npm/alpinejs@3.x.x/dist/cdn.min.js"></script>
|
||
<script src="https://cdn.jsdelivr.net/npm/echarts@5.5.0/dist/echarts.min.js"></script>
|
||
<style>
|
||
@import url('https://fonts.googleapis.com/css2?family=Noto+Sans+SC:wght@300;400;500;700&family=Oxanium:wght@300;400;600;700&display=swap');
|
||
|
||
body {
|
||
font-family: 'Noto Sans SC', sans-serif;
|
||
background-color: #0a0a1a;
|
||
color: #e0e0e0;
|
||
overflow-x: hidden;
|
||
background-image:
|
||
radial-gradient(ellipse 20% 40% at 20% 20%, rgba(10, 80, 180, 0.15), transparent),
|
||
radial-gradient(ellipse 20% 40% at 80% 80%, rgba(100, 10, 150, 0.15), transparent);
|
||
background-attachment: fixed;
|
||
}
|
||
|
||
.font-fui {
|
||
font-family: 'Oxanium', cursive;
|
||
}
|
||
|
||
.glass-card {
|
||
background: rgba(15, 23, 42, 0.6); /* slate-900 with opacity */
|
||
backdrop-filter: blur(20px);
|
||
-webkit-backdrop-filter: blur(20px);
|
||
border: 1px solid rgba(56, 189, 248, 0.2); /* sky-400 with opacity */
|
||
border-radius: 1.5rem; /* rounded-3xl */
|
||
transition: all 0.3s ease;
|
||
position: relative;
|
||
overflow: hidden;
|
||
}
|
||
|
||
.glass-card:before {
|
||
content: '';
|
||
position: absolute;
|
||
top: -50%;
|
||
left: -50%;
|
||
width: 200%;
|
||
height: 200%;
|
||
background: radial-gradient(circle, rgba(56, 189, 248, 0.1) 0%, rgba(56, 189, 248, 0) 60%);
|
||
opacity: 0;
|
||
transition: opacity 0.5s ease;
|
||
transform-origin: center;
|
||
pointer-events: none;
|
||
}
|
||
|
||
.glass-card:hover:before {
|
||
opacity: 1;
|
||
}
|
||
|
||
.glow-text {
|
||
text-shadow: 0 0 8px rgba(56, 189, 248, 0.6);
|
||
}
|
||
|
||
.bento-grid {
|
||
display: grid;
|
||
gap: 1.5rem;
|
||
grid-template-columns: repeat(12, 1fr);
|
||
}
|
||
|
||
.bento-item-1 { grid-column: span 12; }
|
||
.bento-item-2 { grid-column: span 12; md:grid-column: span 8; }
|
||
.bento-item-3 { grid-column: span 12; md:grid-column: span 4; }
|
||
.bento-item-4 { grid-column: span 12; md:grid-column: span 6; }
|
||
.bento-item-5 { grid-column: span 12; md:grid-column: span 6; }
|
||
.bento-item-6 { grid-column: span 12; }
|
||
|
||
@media (min-width: 768px) {
|
||
.bento-item-1 { grid-column: span 12; }
|
||
.bento-item-2 { grid-column: span 8; }
|
||
.bento-item-3 { grid-column: span 4; }
|
||
.bento-item-4 { grid-column: span 5; }
|
||
.bento-item-5 { grid-column: span 7; }
|
||
.bento-item-6 { grid-column: span 12; }
|
||
}
|
||
|
||
.timeline-item {
|
||
position: relative;
|
||
padding-left: 2.5rem;
|
||
padding-bottom: 2rem;
|
||
border-left: 2px solid rgba(56, 189, 248, 0.3);
|
||
}
|
||
|
||
.timeline-item:last-child {
|
||
border-left: 2px solid transparent;
|
||
padding-bottom: 0;
|
||
}
|
||
|
||
.timeline-marker {
|
||
position: absolute;
|
||
left: -0.7rem;
|
||
top: 0;
|
||
width: 1.25rem;
|
||
height: 1.25rem;
|
||
border-radius: 9999px;
|
||
background-color: #0284c7; /* sky-600 */
|
||
border: 4px solid #0c4a6e; /* sky-900 */
|
||
box-shadow: 0 0 15px rgba(56, 189, 248, 0.8);
|
||
}
|
||
|
||
.table-custom thead tr {
|
||
background-color: rgba(56, 189, 248, 0.1);
|
||
border-bottom: 1px solid rgba(56, 189, 248, 0.3);
|
||
}
|
||
|
||
.table-custom tbody tr {
|
||
border-bottom: 1px solid rgba(255, 255, 255, 0.1);
|
||
}
|
||
|
||
.table-custom tbody tr:hover {
|
||
background-color: rgba(56, 189, 248, 0.08);
|
||
}
|
||
|
||
.collapse-title {
|
||
background: rgba(15, 23, 42, 0.7);
|
||
}
|
||
</style>
|
||
</head>
|
||
|
||
<body class="min-h-screen">
|
||
<div class="container mx-auto p-4 sm:p-6 lg:p-8">
|
||
|
||
<!-- Header -->
|
||
<header class="text-center mb-12">
|
||
<h1 class="text-4xl md:text-6xl font-fui font-bold glow-text bg-gradient-to-r from-sky-300 to-indigo-400 text-transparent bg-clip-text mb-2">
|
||
盐酸哌甲酯 概念深度研报
|
||
</h1>
|
||
<p class="text-lg text-slate-400 font-fui">
|
||
AI Investment Research Agent: "价小前投研"
|
||
</p>
|
||
<div class="mt-4 text-xs text-slate-500 max-w-2xl mx-auto">
|
||
呈现方：北京价值前沿科技有限公司 AI投研agent：“价小前投研”。本报告基于公开数据AI合成，不构成任何投资建议，投资需谨慎。
|
||
</div>
|
||
</header>
|
||
|
||
<main class="space-y-12">
|
||
<!-- Concept Event & Timeline Section -->
|
||
<section class="bento-grid">
|
||
<div class="bento-item-1 glass-card p-6 md:p-8">
|
||
<h2 class="text-2xl font-bold font-fui mb-4 text-sky-300">概念核心事件：供需失衡下的国产替代破局</h2>
|
||
<p class="text-slate-300 leading-relaxed">
|
||
盐酸哌甲酯，作为治疗注意缺陷多动障碍(ADHD)的一线核心药物，长期由进口原研药“专注达”垄断。然而，近年来全球供应链问题导致“专注达”在国内频繁断货（<span class="font-bold text-amber-400">超80%三甲医院周期性中断</span>），造成巨大的临床用药缺口。在此背景下，<span class="font-bold text-teal-300">合肥立方制药</span>的盐酸哌甲酯缓释片于2025年4月作为<span class="font-bold text-red-400">国内首仿</span>获批，采用了与原研一致的高壁垒<span class="font-bold text-sky-300">三层渗透泵控释技术</span>。产品预计于<span class="font-bold text-lime-300">2025年Q3末</span>上市，精准填补市场真空，开启了由“长期需求扩张”与“短期供给真空”双重驱动的国产替代新篇章。
|
||
</p>
|
||
</div>
|
||
|
||
<div class="bento-item-2 glass-card p-6 md:p-8">
|
||
<h2 class="text-2xl font-bold font-fui mb-6 text-sky-300">关键时间轴</h2>
|
||
<div class="relative">
|
||
<div class="timeline-item">
|
||
<div class="timeline-marker"></div>
|
||
<p class="font-fui text-lg text-indigo-300">~2024年</p>
|
||
<p class="text-slate-300">原研药“专注达”供应不稳定问题凸显，市场供需矛盾加剧。</p>
|
||
</div>
|
||
<div class="timeline-item">
|
||
<div class="timeline-marker"></div>
|
||
<p class="font-fui text-lg text-indigo-300">2025年4月</p>
|
||
<p class="text-slate-300"><span class="font-semibold text-teal-300">立方制药</span>盐酸哌甲酯缓释片获批《药品注册证书》，成为国内首仿。</p>
|
||
</div>
|
||
<div class="timeline-item">
|
||
<div class="timeline-marker"></div>
|
||
<p class="font-fui text-lg text-indigo-300">2025年Q3 (预期)</p>
|
||
<p class="text-slate-300">立方制药产品正式上市销售，概念从预期走向现实。</p>
|
||
</div>
|
||
<div class="timeline-item">
|
||
<div class="timeline-marker"></div>
|
||
<p class="font-fui text-lg text-indigo-300">2026年 (预期)</p>
|
||
<p class="text-slate-300">该单品有望为立方制药新增<span class="font-semibold text-lime-400">过亿收入</span>，业绩开始兑现。</p>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
<div class="bento-item-3 glass-card p-6 md:p-8 flex flex-col">
|
||
<h2 class="text-2xl font-bold font-fui mb-4 text-sky-300">市场潜力一览</h2>
|
||
<div id="market-potential-chart" class="flex-grow w-full h-64"></div>
|
||
</div>
|
||
</section>
|
||
|
||
<!-- Core Insight Section -->
|
||
<section class="space-y-6">
|
||
<div class="text-center">
|
||
<h2 class="text-3xl font-bold font-fui bg-gradient-to-r from-sky-300 to-indigo-400 text-transparent bg-clip-text">
|
||
深度洞察与逻辑推演
|
||
</h2>
|
||
<p class="text-slate-400 mt-2">从基本面驱动的业绩兑现阶段剖析概念价值</p>
|
||
</div>
|
||
|
||
<div class="bento-grid">
|
||
<div class="bento-item-4 glass-card p-6">
|
||
<h3 class="font-fui text-xl font-bold text-sky-300 mb-3">核心逻辑：三重叙事共振</h3>
|
||
<ul class="space-y-3 text-slate-300">
|
||
<li><strong class="text-teal-300">供给真空填补:</strong> 非传统价格战仿制，而是在原研药断供背景下对数亿元空白市场的“接管”，增量逻辑确定性极高。</li>
|
||
<li><strong class="text-sky-300">技术壁垒护城河:</strong> “三层渗透泵控释技术”与原研一致，壁垒高，预计<span class="text-amber-400">3-5年内国产唯一</span>，竞争格局极佳。</li>
|
||
<li><strong class="text-lime-300">需求蓝海开拓:</strong> 国内ADHD就诊率仅10%，对应超2000万患儿。国产药稳定供应将驱动渗透率提升，测算<span class="text-amber-400">1%渗透率即对应25亿+空间</span>。</li>
|
||
</ul>
|
||
</div>
|
||
|
||
<div class="bento-item-5 glass-card p-6">
|
||
<h3 class="font-fui text-xl font-bold text-sky-300 mb-3">关键催化剂与发展路径</h3>
|
||
<ul class="space-y-3 text-slate-300">
|
||
<li><strong>近期 (3-6月):</strong> <span class="badge badge-info badge-outline font-fui">产品上市</span> (25Q3末), <span class="badge badge-success badge-outline font-fui">首批销售数据披露</span>, <span class="badge badge-warning badge-outline font-fui">省级医保准入</span>。</li>
|
||
<li><strong>中期 (1-3年):</strong> 完成对“专注达”的市场替代，成为领导者；通过<span class="text-red-400">纳入国家医保</span>实现“以价换量”，引爆市场渗透率。</li>
|
||
<li><strong>长期 (3-5年+):</strong> 配合学术推广，提升社会对ADHD的整体诊疗率，做大市场“蛋糕”。借鉴美国Jornay PM成功经验，通过市场教育扩大份额。</li>
|
||
</ul>
|
||
</div>
|
||
|
||
<div class="bento-item-6 glass-card p-6">
|
||
<h3 class="font-fui text-xl font-bold text-sky-300 mb-3">潜在风险与预期差</h3>
|
||
<div class="grid md:grid-cols-2 gap-6">
|
||
<div>
|
||
<h4 class="font-semibold text-rose-400 mb-2">主要风险点</h4>
|
||
<ul class="list-disc list-inside space-y-2 text-slate-300">
|
||
<li><strong>商业化风险:</strong> 作为一类精神药品，营销推广受严格限制，考验专业学术推广能力及医院准入速度。</li>
|
||
<li><strong>竞争风险:</strong> 潜在竞争对手（如路演曾提及的<span class="text-amber-400">人福医药</span>）研发进度超预期，可能缩短独占窗口期。</li>
|
||
<li><strong>政策风险:</strong> 长期看，若多家仿制药上市，仍面临集采导致利润空间压缩的风险。</li>
|
||
</ul>
|
||
</div>
|
||
<div>
|
||
<h4 class="font-semibold text-amber-300 mb-2">核心预期差分析</h4>
|
||
<p class="text-slate-300 leading-relaxed">
|
||
市场普遍共识是“立方制药独享3-5年市场”。然而，一份早期（2024.06）路演纪要曾提及竞争格局为“仅立方/人福两家”，这与所有更新的信源（强调立方“国产唯一”）<span class="text-red-400 font-bold">存在明显矛盾</span>。
|
||
<br><br>
|
||
这是当前最大的预期差和潜在风险点。需持续跟踪人福医药的管线进展，以验证或证伪立方制药的独占期是否如市场预期的那么稳固。
|
||
</p>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</section>
|
||
|
||
<!-- Raw Intelligence Briefing -->
|
||
<section x-data="{ openTab: 'news' }">
|
||
<div class="text-center mb-6">
|
||
<h2 class="text-3xl font-bold font-fui bg-gradient-to-r from-sky-300 to-indigo-400 text-transparent bg-clip-text">
|
||
原始情报摘要
|
||
</h2>
|
||
</div>
|
||
<div class="join join-vertical w-full">
|
||
<div class="collapse collapse-arrow join-item border border-base-300 glass-card">
|
||
<input type="radio" name="my-accordion-4" checked="checked" />
|
||
<div class="collapse-title text-xl font-medium font-fui text-sky-300">
|
||
新闻数据摘要
|
||
</div>
|
||
<div class="collapse-content text-slate-300 p-4 leading-relaxed">
|
||
<ul class="list-disc list-inside space-y-2">
|
||
<li><strong>药品核心信息:</strong> 盐酸哌甲酯缓释片，属<span class="font-semibold text-red-400">第一类精神药品</span>，用于治疗ADHD，是临床一线用药。采用与“专注达”一致的<span class="font-semibold text-sky-400">三层渗透泵控释技术</span>，壁垒高。</li>
|
||
<li><strong>市场需求:</strong> 我国儿童ADHD患病率6.26%（约<span class="font-semibold text-amber-400">2300万</span>），成人患病率3%，潜在治疗需求超8000万人，但就诊率仅10%。</li>
|
||
<li><strong>获批与上市:</strong> 立方制药产品为<span class="font-semibold text-teal-300">首仿获批</span>（2025年4月），预计<span class="font-semibold text-lime-300">2025年三季度末上市销售</span>。</li>
|
||
<li><strong>竞争格局:</strong> 境内仅一家进口（西安杨森“专注达”），暂无其他企业进入临床或申报。预计立方制药为<span class="font-semibold text-fuchsia-400">3-5年内国产唯一</span>。</li>
|
||
<li><strong>供给侧问题:</strong> 原研药“专注达”全球供应链告急，国内超<span class="font-semibold text-orange-400">80%三甲医院周期性断货</span>，市场供不应求。</li>
|
||
<li><strong>财务预期:</strong> 具备<span class="font-semibold">大单品潜质</span>，渗透率若达1%，市场空间超25亿。有望为立方制药26年新增<span class="font-semibold text-green-400">过亿收入</span>。用药成本约1000元/月。</li>
|
||
</ul>
|
||
</div>
|
||
</div>
|
||
<div class="collapse collapse-arrow join-item border border-base-300 glass-card">
|
||
<input type="radio" name="my-accordion-4" />
|
||
<div class="collapse-title text-xl font-medium font-fui text-sky-300">
|
||
路演纪要摘要
|
||
</div>
|
||
<div class="collapse-content text-slate-300 p-4 leading-relaxed">
|
||
<p class="font-bold mb-2">国投证券 (2024-06-02):</p>
|
||
<ul class="list-disc list-inside space-y-1 pl-4 mb-4">
|
||
<li>将立方制药的盐酸哌甲酯缓释片列为“新品放量”的核心逻辑之一。</li>
|
||
<li>提及竞争格局良好，当时纪要称“仅立方/人福两家”，此信息点与后期研报新闻存在差异，需重点关注。</li>
|
||
</ul>
|
||
<p class="font-bold mb-2">Collegium Pharmaceutical (美国, 2025-05-09):</p>
|
||
<ul class="list-disc list-inside space-y-1 pl-4">
|
||
<li>其哌甲酯产品Jornay PM为公司核心增长驱动，Q1营收同比增长24%，预计25年营收超1.35亿美元。</li>
|
||
<li>Jornay在长效品牌哌甲酯市场占有率达20.3%，其增长主要来自对仿制药（即释剂型）的转换。</li>
|
||
<li>为国产哌甲酯的市场教育和份额扩张提供了可借鉴的成功路径。</li>
|
||
</ul>
|
||
</div>
|
||
</div>
|
||
<div class="collapse collapse-arrow join-item border border-base-300 glass-card">
|
||
<input type="radio" name="my-accordion-4" />
|
||
<div class="collapse-title text-xl font-medium font-fui text-sky-300">
|
||
研报观点摘要
|
||
</div>
|
||
<div class="collapse-content text-slate-300 p-4 leading-relaxed">
|
||
<ul class="list-disc list-inside space-y-2">
|
||
<li><strong>产品定位:</strong> 国内首仿获批，独家首仿精1类药物。</li>
|
||
<li><strong>上市进展:</strong> 预计三季度末上市销售，正在进行准入、入院工作，有望成为核心增长点。</li>
|
||
<li><strong>技术优势:</strong> 强调“三层芯片控释技术”（渗透泵）的核心壁垒，立方制药拥有完整的技术平台和自有原料药供应，成本可控。</li>
|
||
<li><strong>竞争格局:</strong> 明确指出同类制剂国内仅原研“专注达”上市，且供应不稳定，为立方制药创造了绝佳市场窗口。</li>
|
||
<li><strong>投资评级:</strong> 多家券商一致给予“买入”评级，看好公司发展，认为集采风险已出清，哌甲酯将成为核心增长点。</li>
|
||
</ul>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</section>
|
||
|
||
<!-- Stock List Section -->
|
||
<section>
|
||
<div class="text-center mb-6">
|
||
<h2 class="text-3xl font-bold font-fui bg-gradient-to-r from-sky-300 to-indigo-400 text-transparent bg-clip-text">
|
||
产业链核心标的
|
||
</h2>
|
||
</div>
|
||
<div class="overflow-x-auto glass-card p-2">
|
||
<table class="table w-full table-custom">
|
||
<thead>
|
||
<tr>
|
||
<th class="text-sky-300 font-fui">股票名称</th>
|
||
<th class="text-sky-300 font-fui">股票代码</th>
|
||
<th class="text-sky-300 font-fui">产业链环节</th>
|
||
<th class="text-sky-300 font-fui">核心逻辑</th>
|
||
</tr>
|
||
</thead>
|
||
<tbody>
|
||
<tr>
|
||
<td class="font-semibold text-teal-200">立方制药</td>
|
||
<td><a href="https://valuefrontier.cn/company?scode=003020" target="_blank" class="link link-hover text-sky-400">003020</a></td>
|
||
<td><span class="badge badge-primary badge-outline">核心产品</span></td>
|
||
<td class="text-sm">2025年4月获批国内首仿盐酸哌甲酯缓释片，采用高壁垒三层芯渗透泵技术，打破进口垄断，逻辑最纯粹。</td>
|
||
</tr>
|
||
<tr>
|
||
<td class="font-semibold text-white">兄弟科技</td>
|
||
<td><a href="https://valuefrontier.cn/company?scode=002562" target="_blank" class="link link-hover text-sky-400">002562</a></td>
|
||
<td><span class="badge badge-info badge-outline">产品</span></td>
|
||
<td class="text-sm">子公司持有盐酸哌甲酯片（普通片剂）生产批文。</td>
|
||
</tr>
|
||
<tr>
|
||
<td class="font-semibold text-white">华海药业</td>
|
||
<td><a href="https://valuefrontier.cn/company?scode=600521" target="_blank" class="link link-hover text-sky-400">600521</a></td>
|
||
<td><span class="badge badge-info badge-outline">产品</span></td>
|
||
<td class="text-sm">制剂产品盐酸哌甲酯片（普通片剂）获美国FDA批准，主攻海外市场。</td>
|
||
</tr>
|
||
<tr>
|
||
<td class="font-semibold text-white">华润双鹤</td>
|
||
<td><a href="https://valuefrontier.cn/company?scode=600062" target="_blank" class="link link-hover text-sky-400">600062</a></td>
|
||
<td><span class="badge badge-info badge-outline">产品</span></td>
|
||
<td class="text-sm">与祐儿医药合作开发两款盐酸哌甲酯缓释新药，处于布局阶段。</td>
|
||
</tr>
|
||
<tr>
|
||
<td class="font-semibold text-white">交大昂立</td>
|
||
<td><a href="https://valuefrontier.cn/company?scode=600530" target="_blank" class="link link-hover text-sky-400">600530</a></td>
|
||
<td><span class="badge badge-info badge-outline">产品</span></td>
|
||
<td class="text-sm">通过收购泰凌医药获得盐酸哌甲酯片（普通片剂）生产批文。</td>
|
||
</tr>
|
||
<tr>
|
||
<td class="font-semibold text-white">中关村</td>
|
||
<td>-</td>
|
||
<td><span class="badge badge-info badge-outline">产品</span></td>
|
||
<td class="text-sm">子公司获得盐酸哌甲酯缓释咀嚼片项目的专利申请权，处于早期布局。</td>
|
||
</tr>
|
||
<tr>
|
||
<td class="font-semibold text-white">善水科技</td>
|
||
<td><a href="https://valuefrontier.cn/company?scode=301190" target="_blank" class="link link-hover text-sky-400">301190</a></td>
|
||
<td><span class="badge badge-accent badge-outline">上游中间体</span></td>
|
||
<td class="text-sm">生产氯代吡啶系列产品，是盐酸哌甲酯的重要中间体。</td>
|
||
</tr>
|
||
<tr>
|
||
<td class="font-semibold text-white">新和成</td>
|
||
<td>-</td>
|
||
<td><span class="badge badge-accent badge-outline">上游中间体</span></td>
|
||
<td class="text-sm">哌啶类中间体潜在供应商。</td>
|
||
</tr>
|
||
<tr>
|
||
<td class="font-semibold text-white">中国医药</td>
|
||
<td><a href="https://valuefrontier.cn/company?scode=600056" target="_blank" class="link link-hover text-sky-400">600056</a></td>
|
||
<td><span class="badge badge-secondary badge-outline">运输分销</span></td>
|
||
<td class="text-sm">子公司具备第一类精神药品运输资质，覆盖盐酸哌甲酯片。</td>
|
||
</tr>
|
||
<tr>
|
||
<td class="font-semibold text-white">国药控股</td>
|
||
<td>-</td>
|
||
<td><span class="badge badge-secondary badge-outline">运输分销</span></td>
|
||
<td class="text-sm">港股。下属公司获批运输第一类精神药品，包括盐酸哌甲酯缓释片。</td>
|
||
</tr>
|
||
</tbody>
|
||
</table>
|
||
</div>
|
||
</section>
|
||
</main>
|
||
|
||
<footer class="text-center mt-16">
|
||
<p class="text-xs text-slate-600">
|
||
本报告由北京价值前沿科技有限公司的AI投研agent“价小前投研”基于公开数据合成，所有信息仅供参考，不构成任何投资建议。投资有风险，决策需谨慎。
|
||
</p>
|
||
</footer>
|
||
</div>
|
||
<script>
|
||
document.addEventListener('DOMContentLoaded', function () {
|
||
var chartDom = document.getElementById('market-potential-chart');
|
||
var myChart = echarts.init(chartDom, 'dark');
|
||
var option;
|
||
|
||
option = {
|
||
backgroundColor: 'transparent',
|
||
title: {
|
||
text: '我国儿童ADHD市场潜力',
|
||
subtext: '(数据来源：研报估算)',
|
||
left: 'center',
|
||
textStyle: {
|
||
color: '#e0e0e0',
|
||
fontFamily: 'Noto Sans SC'
|
||
},
|
||
subtextStyle: {
|
||
color: '#a0a0a0'
|
||
}
|
||
},
|
||
tooltip: {
|
||
trigger: 'item',
|
||
formatter: '{a} <br/>{b} : {c}万人 ({d}%)'
|
||
},
|
||
legend: {
|
||
orient: 'vertical',
|
||
left: 'left',
|
||
top: 'bottom',
|
||
textStyle: {
|
||
color: '#e0e0e0'
|
||
}
|
||
},
|
||
series: [
|
||
{
|
||
name: '患者分布',
|
||
type: 'pie',
|
||
radius: ['45%', '70%'],
|
||
avoidLabelOverlap: false,
|
||
itemStyle: {
|
||
borderRadius: 10,
|
||
borderColor: 'rgba(15, 23, 42, 0.8)',
|
||
borderWidth: 2
|
||
},
|
||
label: {
|
||
show: false,
|
||
position: 'center'
|
||
},
|
||
emphasis: {
|
||
label: {
|
||
show: true,
|
||
fontSize: '24',
|
||
fontWeight: 'bold',
|
||
color: '#FFFFFF'
|
||
}
|
||
},
|
||
labelLine: {
|
||
show: false
|
||
},
|
||
data: [
|
||
{ value: 2070, name: '未就诊潜在市场', itemStyle: { color: '#083358' } },
|
||
{ value: 230, name: '已就诊存量市场', itemStyle: { color: '#0ea5e9' } },
|
||
]
|
||
}
|
||
]
|
||
};
|
||
|
||
option && myChart.setOption(option);
|
||
window.addEventListener('resize', myChart.resize);
|
||
});
|
||
</script>
|
||
</body>
|
||
</html> |